{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:54:37Z","timestamp":1793073277731,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.109911","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:28:36Z","timestamp":1774970916000},"page":"109911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cerebrospinal fluid heparan sulfate as a biomarker for neuronopathic mucopolysaccharidoses: Rationale and regulatory challenges"],"prefix":"10.1016","volume":"148","author":[{"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia I.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Matthew","family":"Ellinwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hemsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.109911_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","article-title":"The Mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"issue":"Suppl. 5","key":"10.1016\/j.ymgme.2026.109911_bb0010","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ymgme.2026.109911_bb0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jmedgenet-2021-108061","article-title":"Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency","volume":"59","author":"Verheyen","year":"2022","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2026.109911_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/diagnostics11020273","article-title":"Epidemiology of mucopolysaccharidoses update","volume":"11","author":"\u00c7elik","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ymgme.2026.109911_bb0025","article-title":"Newborn screening for mucopolysaccharidoses: measurement of glycosaminoglycans by LC-MS\/MS","volume":"22","author":"Stapleton","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.109911_bb0030","article-title":"Biomarkers in patients with mucopolysaccharidosis type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"10","key":"10.1016\/j.ymgme.2026.109911_bb0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3390\/biom15101448","article-title":"Mucopolysaccharidoses-what clinicians need to know: A clinical, biochemical, and molecular overview","volume":"15","author":"Lipi\u0144ski","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109911_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2020.01011","article-title":"A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management","volume":"9","author":"Zhou","year":"2020","journal-title":"Intractable Rare Dis. Res."},{"issue":"16","key":"10.1016\/j.ymgme.2026.109911_bb0045","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/diagnostics14161734","article-title":"Mucopolysaccharidosis type IIIE: A real human disease or a diagnostic pitfall?","volume":"14","author":"Wi\u015bniewska","year":"2024","journal-title":"Diagnostics (Basel)."},{"issue":"17","key":"10.1016\/j.ymgme.2026.109911_bb0050","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.3390\/ijms25179570","article-title":"Mucopolysaccharidosis-plus syndrome: is this a type of mucopolysaccharidosis or a separate kind of metabolic disease?","volume":"25","author":"Cyske","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2013.11.014","article-title":"Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the \u03b1-L-iduronidase gene in hurler-Scheie syndrome","volume":"111","author":"Ahmed","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0060","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2026.109911_bb0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109911_bb0070","article-title":"Haruo shintaku, torayuki okuyama, intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: final report of 5-year results from a japanese open-label phase 1\/2 study","volume":"140","author":"Joo-Hyun","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"20","key":"10.1016\/j.ymgme.2026.109911_bb0075","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109911_bb0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, Targeting Neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol Ther."},{"key":"10.1016\/j.ymgme.2026.109911_bb0085","author":"Biomarker"},{"key":"10.1016\/j.ymgme.2026.109911_bb0090","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]","author":"FDA-NIH Biomarker Working Group","year":"2016"},{"key":"10.1016\/j.ymgme.2026.109911_bb0095","series-title":"The Metabolic and Molecular Bases of Inherited Disease","article-title":"The Mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"issue":"3","key":"10.1016\/j.ymgme.2026.109911_bb0100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jnc.15891","article-title":"Biomarkers for predicting disease course in sanfilippo syndrome: an urgent unmet need in childhood-onset dementia","volume":"166","author":"Winner","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2026.109911_bb0105","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3390\/ijms21072515","article-title":"Pathogenesis of mucopolysaccharidoses, an update","volume":"21","author":"Fecarotta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jnc.14632","article-title":"The role of innate immunity in mucopolysaccharide diseases","volume":"149","author":"Parker","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2026.109911_bb0115","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/ijms23041999","article-title":"Innate immunity in mucopolysaccharide diseases","volume":"23","author":"Mandolfo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109911_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/genes14020271","article-title":"Expression of long noncoding RNAs in fibroblasts from mucopolysaccharidosis patients","volume":"14","author":"Cyske","year":"2023","journal-title":"Genes (Basel)"},{"issue":"24","key":"10.1016\/j.ymgme.2026.109911_bb0125","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.3390\/ijms252413447","article-title":"The role of gene expression dysregulation in the pathogenesis of mucopolysaccharidosis: A comparative analysis of shared and specific molecular markers in neuronopathic and non-Neuronopathic types of the disease","volume":"25","author":"Wi\u015bniewska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109911_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/ijms24010477","article-title":"Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets","volume":"24","author":"Leal","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0135","series-title":"Essentials of Glycobiology","first-page":"207","article-title":"Proteoglycans and sulfated glycosaminoglycans","author":"Lindahl","year":"2015"},{"key":"10.1016\/j.ymgme.2026.109911_bb0140","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/clinchem\/35.3.374","article-title":"Diagnostic test for mucopolysaccharidosis. i. Direct method for quantifying excessive urinary glycosaminoglycan excretion","volume":"35","author":"Whitley","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2026.109911_bb0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/clinchem\/38.6.803","article-title":"Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue","volume":"38","author":"De Jong","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2026.109911_bb0150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1203\/01.PDR.0000141987.69757.DD","article-title":"Disease-specific markers for the mucopolysaccharidoses","volume":"56","author":"Fuller","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2026.109911_bb0155","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41436-018-0136-z","article-title":"Disease and subtype-specific signatures enable precise diagnosis of the mucopolysaccharidoses","volume":"21","author":"Saville","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.109911_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107632","article-title":"Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis","volume":"140","author":"Herbst","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2026.109911_bb0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.122.001119","article-title":"Tralesinidase alfa enzyme replacement therapy prevents disease manifestations in a canine model of mucopolysaccharidosis type IIIB","volume":"382","author":"Ellinwood","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109911_bb0175","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165076","article-title":"A phase I\/II study on intracerebroventricular tralesinidase alfa in patients with sanfilippo syndrome type b","volume":"133","author":"Muschol","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2026.109911_bb0180","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-009-9036-3","article-title":"Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis i","volume":"33","author":"Tomatsu","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109911_bb0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.aca.2016.06.054","article-title":"UPLC-MS\/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses","volume":"936","author":"Auray-Blais","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.ymgme.2026.109911_bb0190","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2026.109911_bb0195","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4155\/bio-2019-0095","article-title":"Robust LC-MS\/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA","volume":"11","author":"Makower","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ymgme.2026.109911_bb0200","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.3390\/ijms21155449","article-title":"High-throughput liquid chromatography-tandem mass spectrometry quantification of glycosaminoglycans as biomarkers of mucopolysaccharidosis II","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0205","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4155\/bio.15.243","article-title":"A novel LC-MS\/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients","volume":"8","author":"Naimy","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ymgme.2026.109911_bb0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ab.2018.12.013","article-title":"Glycosaminoglycans in human cerebrospinal fluid determined by LC-MS\/MS MRM","volume":"567","author":"Yu","year":"2019","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2026.109911_bb0215","doi-asserted-by":"crossref","first-page":"C1091","DOI":"10.1152\/ajpcell.00944.2024","article-title":"Utilizing 13C-Labeled internal standards to advance the analysis of heparan sulfate","volume":"328","author":"Wang","year":"2025","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ymgme.2026.109911_bb0220","doi-asserted-by":"crossref","first-page":"38305","DOI":"10.1038\/srep38305","article-title":"Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H","volume":"6","author":"Raymond","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2026.109911_bb0225","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.3390\/ijms21155188","article-title":"Characterization of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in neuronopathic MPS II patients","volume":"15","author":"Bhalla","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107709","article-title":"Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: final report of 5-year results from a japanese open-label phase 1\/2 study","volume":"140","author":"Seo","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0235","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109911_bb0240","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymgme.2022.06.008","article-title":"Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: results from an open, non-controlled, multicenter study","volume":"136","author":"Harmatz","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpeds.2022.06.005","article-title":"Longitudinal natural history of pediatric subjects affected with mucopolysaccharidosis IIIB","volume":"249","author":"Okur","year":"2022","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.109911_bb0250","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ymgme.2019.05.005","article-title":"Evaluation of biomarkers for sanfilippo syndrome","volume":"128","author":"Saville","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.640547","article-title":"Surrogate cerebrospinal fluid biomarkers for assessing the efficacy of gene therapy in hurler syndrome","volume":"12","author":"Haseloff","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2026.109911_bb0260","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/jcm9020396","article-title":"Brain pathology in mucopolysaccharidoses (MPS) patients with neurological forms","volume":"9","author":"Viana","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2026.109911_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035787","article-title":"Neuropathology in mouse models of mucopolysaccharidosis type i, IIIA, and IIIB","volume":"7","author":"Wilkinson","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ymgme.2026.109911_bb0270","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/metabo4041088","article-title":"Distribution of heparan sulfate oligosaccharides in murine mucopolysaccharidosis type IIIA","volume":"4","author":"Mason","year":"2014","journal-title":"Metabolites"},{"key":"10.1016\/j.ymgme.2026.109911_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","article-title":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","volume":"125","author":"Tanaka","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0280","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0285","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1089\/hum.2020.253","article-title":"Systemic scAAV9.U1a.hSGSH delivery corrects brain biochemistry in mucopolysaccharidosis type IIIA at early and later stages of disease","volume":"32","author":"Saville","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2026.109911_bb0290","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10545-018-0221-0","article-title":"The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: Heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology","volume":"41","author":"Sohn","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109911_bb0295","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtm.2022.05.002","article-title":"Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice","volume":"10","author":"Morimoto","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2026.109911_bb0300","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2026.109911_bb0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9790-8","article-title":"Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA huntaway dog brain","volume":"38","author":"King","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109911_bb0310","article-title":"Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice","volume":"21","author":"Gustavsson","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2026.109911_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0328941","article-title":"Recombinant human alpha-N-acetylglucosamine-6-sulfatase delivered to sanfilippo d mice with repeated intracerebroventricular injections corrects CNS pathology","volume":"20","author":"Austin","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.ymgme.2026.109911_bb0320","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","article-title":"Intrathecal enzyme replacement for hurler syndrome: Biomarker association with neurocognitive outcomes","volume":"11","author":"Eisengart","year":"2019","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109911_bb0325","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109911_bb0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa2508681","article-title":"An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II","volume":"394","author":"Muenzer","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109911_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108820","article-title":"Treatment with UX111 gene therapy rapidly reduced heparan sulfate (HS) exposure in cerebrospinal fluid (CSF) and improved long-term cognitive function in children with mucopolysaccharidosis type IIIA (MPS IIIA)","volume":"144","author":"Lau","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0340","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2020.07.006","article-title":"Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses","volume":"131","author":"Derrick-Roberts","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0345","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2019.08.008","article-title":"Sphingolipid dyshomeostasis in the brain of the mouse model of mucopolysaccharidosis type IIIA","volume":"129","author":"Saville","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0350","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3727\/096368914X676916","article-title":"Repeated administrations of human umbilical cord blood cells improve disease outcomes in a mouse model of sanfilippo syndrome type III b","volume":"23","author":"Willing","year":"2014","journal-title":"Cell Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109911_bb0355","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/brainsci10010056","article-title":"Neurofilaments: the C-reactive protein of neurology","volume":"10","author":"Lambertsen","year":"2020","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109911_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109055","article-title":"A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2\/3 clinical trial and extension study of intrathecal idursulfase","volume":"144","author":"Argueta","year":"2025","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109911_bb0365","doi-asserted-by":"crossref","first-page":"108535","DOI":"10.1016\/j.ymgme.2024.108535","article-title":"Community consensus for heparan sulfate as a biomarker to support accelerated approval in neuronopathic mucopolysaccharidoses","volume":"142","author":"Muenzer","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0370","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/pds.4975","article-title":"Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms","volume":"29","author":"Burcu","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ymgme.2026.109911_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002966","article-title":"Noncompletion and nonpublication of trials studying rare diseases: a cross-sectional analysis","volume":"16","author":"Rees","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymgme.2026.109911_bb0380","author":"Berasi"},{"key":"10.1016\/j.ymgme.2026.109911_bb0385","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13052-018-0561-2","article-title":"Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses","volume":"44","author":"Barone","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109911_bb0390","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s13023-024-03463-9","article-title":"Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with mucopolysaccharidosis type II: A position statement","volume":"19","author":"Giugliani","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.109911_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1441807","article-title":"Unlocking the full potential of rare disease drug development: exploring the not-for-profit sectors contributions to drug development and access","volume":"15","author":"Vavassori","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymgme.2026.109911_bb0400","author":"Twenty-First Century Cures Act"},{"key":"10.1016\/j.ymgme.2026.109911_bb0405","author":"Accelerated Approval"},{"key":"10.1016\/j.ymgme.2026.109911_bb0410","author":"Conditional Marketing Authorisation"},{"key":"10.1016\/j.ymgme.2026.109911_bb0415","author":"ILAP application guidance"},{"key":"10.1016\/j.ymgme.2026.109911_bb0420","author":"Guidance Document"},{"key":"10.1016\/j.ymgme.2026.109911_bb0425","author":"Provisional Approval Pathway: prescription medicines"},{"key":"10.1016\/j.ymgme.2026.109911_bb0430","author":"Overview of Orphan Drug\/Medical Device Designation System"},{"issue":"20","key":"10.1016\/j.ymgme.2026.109911_bb0435","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109911_bb0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2019.09.001","article-title":"Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis i","volume":"129","author":"Vera","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"22","key":"10.1016\/j.ymgme.2026.109911_bb0445","doi-asserted-by":"crossref","DOI":"10.1172\/JCI195268","article-title":"Reduced heparan sulfate levels in cerebrospinal fluid reflect brain neuron correction in sanfilippo b mice","volume":"135","author":"Le","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109911_bb0450","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ymgme.2012.05.003","article-title":"Biomarkers for the mucopolysaccharidoses: discovery and clinical utility","volume":"106","author":"Clarke","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109911_bb0455","article-title":"Biomarkers in patients with mucopolysaccharidosis type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"541","key":"10.1016\/j.ymgme.2026.109911_bb0460","article-title":"Untargeted LC-HRMS metabolomics reveals candidate biomarkers for mucopolysaccharidoses","volume":"15","author":"Torres","year":"2023","journal-title":"Clin. Chim. Acta"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:01:20Z","timestamp":1787670080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226001940"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109911","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid heparan sulfate as a biomarker for neuronopathic mucopolysaccharidoses: Rationale and regulatory challenges","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109911"}}